Reactive Metabolites as Key Intermediates in Pharmacologic and Toxicologic Responses: Examples from Chemical Carcinogenesis

  • Elizabeth C. Miller
  • James A. Miller
Part of the Advances in Experimental Medicine and Biology book series (AEMB)


Five years have elapsed since the 1975 international conference on “Active Intermediates: Formation, Toxicity, and Inactivation” at the University of Turku, Turku, Finland. That conference and the volume that contained the record of its proceedings (Jollow et al., 1977) were landmarks in the field. Thus, that meeting was the first comprehensive international conference on the metabolic activation, reactivity, and conjugation of the wide range of biologically active xenobiotic molecules and on some of the biological consequences of the reactions of strong electrophilic reactants with cellular molecules. The international conference that we are opening today should provide us with an important up-dating of those data and concepts. It is a pleasure to have at this meeting many of those who participated in the Turku conference, as well as many other scientists contributing to this field.


Chemical Carcinogen Reactive Metabolite Pharmacologic Response Carcinogenic Activity Chemical Carcinogenesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ames, B. N., Durston, W. E., Yamasaki, E., and Lee, F. D., 1973, Carcinogens are mutagens: A simple test system combining liver homogenates for activation and bacteria for detection, Proc. Natl. Acad. Sci. U.S.A., 70: 2281.PubMedCentralPubMedCrossRefGoogle Scholar
  2. Bartsch, H., Kuroki, T., Roberfroid, M., and Malaveille, C., 1980, Metabolic activation sytems in vitro for carcinogen/mutagen screening tests, in: “Chemical Mutagens,” Vol. 7, A. Hollander, ed., Plenum Press, New York/London, in press.Google Scholar
  3. Berenblum, I., 1974, “Carcinogenesis as a Biological Problem,” North-Holland Publishing Co., Amsterdam/Oxford.Google Scholar
  4. Berry, D. L., Bracken, W. M., Fischer, S. M., Viaje, and Slaga, T. J., 1978, Metabolic conversion of 12–0-tetradecanoylphorbol-13-acetate in adult and newborn mouse skin and mouse liver microsomes, Cancer Res., 38: 2301.PubMedGoogle Scholar
  5. Borchert, P., Miller, J. A., Miller, E. C., and Shires, T. K., 1973, l′-Hydroxysafrole, a proximate carcinogenic metabolite of safrole in the rat and mouse, Cancer Res., 33: 590.PubMedGoogle Scholar
  6. Borchert, P., Wislocki, P. G., Miller, J. A., and Miller, E. C., 1973, The metabolism of the naturally occurring hepatocarcinogen safrole to l′-hydroxysafrole and the electrophilic reactivity of l′-acetoxysafrole, Cancer Res., 33: 575.PubMedGoogle Scholar
  7. Boutwell, R. K., 1964, Some biological aspects of skin carcinogenesis, Progr. Exp. Tumor Res., 4: 207.PubMedGoogle Scholar
  8. Chasseaud, L. F., 1979, The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents, Adv. Cancer Res., 29: 175.PubMedGoogle Scholar
  9. Delaforge, M., Janiaud, P., Chessebeuf, M., Padieu, P., and Maume, B. F., 1978, Possible occurrence of the epoxide-diol metabolic pathway for hepatocarcinogenic safrole in cultured rat liver cells, as compared with whole animal: A metabolic study by mass spectrometry, in: “Mass Spectrometry in Biochemistry and Medicine,” A. Frigerio and N. Castaginoli, ed., Spectrum Publications, New York.Google Scholar
  10. Drinkwater, N. R., Miller, E. C., and Miller, J. A., 1980, Estimation of apurinic/apyrimidinic sites and phosphotriesters in DNA treated with electrophilic carcinogens and mutagens, Biochemistry, in press.Google Scholar
  11. Drinkwater, N. R., Miller, E. C., Miller, J. A., and Pitot, H. C., 1976, The hepatocarcinogenicity of estragole (1-allyl-4methoxybenzene) and l′-hydroxyestragole in the mouse and the mutagenicity of l′-acetoxyestragole in bacteria, J. Natl. Cancer Inst., 57: 1323.PubMedGoogle Scholar
  12. Emmelot, P., and Kriek, E., ed., 1979, “Environmental Carcinogenesis: Occurrence, Risk Evaluation, and Mechanisms,” Elsevier/North Holland, Amsterdam.Google Scholar
  13. Fairchild, E. J., Lewis, R. J., and Tatken, R. L., ed., 1978, “Registry of Toxic Effects of Chemical Substances,” 1977 ed., Publication No. (NIOSH) 78–104A, U.S. Government Publishing Office, Washington, D.C.Google Scholar
  14. Garfield, E., Revesz, G. S., and Batzig, J. H., 1973, The synthetic chemical literature from 1960 to 1969, Nature, 242: 307.CrossRefGoogle Scholar
  15. Goldstein, A., Aronow, L., and Kalman, S. M., 1974, “Principles of Drug Action: The Basis of Pharmacology,” 2nd ed., John Wiley & Sons, New York/London.Google Scholar
  16. Green, M. H. L., 1979, Mutagenic consequences of chemical reaction with DNA, in: “Chemical Carcinogens and DNA,” P. L. Grover, ed., Vol. 2, p. 95, CRC Press, Boca Raton, Fla.Google Scholar
  17. Grover, P. L., ed., 1979, “Chemical Carcinogens and DNA,” Vols. 1 and 2, CRC Press, Boca Raton, Fla.Google Scholar
  18. Hecker, E., 1977, Structure-activity relationships in diterpene esters irritant and cocarcinogenic to mouse skin, in: “Carcinogenesis, Vol. 2, Mechanisms of Tumor Promotion and Cocarcinogenesis,” T. J. Slaga, A. Sivak, and R. K. Boutwell, ed., Raven Press, New York.Google Scholar
  19. Jollow, D. J.,Kocsis, J. J., Snyder, R., and Vainio, H., ed., 1977, “Biological Reactive Intermediates,” Plenum Press, New York/London.Google Scholar
  20. Kasper, C. B., 1976, Chemical and enzymic composition of the nuclear envelope. In: “Cell Biology,” P. L. Altman and D. D. Katz, ed., p. 395, Federation of American Societies for Experimental Biology, Bethesda, MD.Google Scholar
  21. Loeb, L. A., Sirover, M. A., Weymouth, L. A., Dube, D. K., Seal, G., Agarwal, S. S., and Katz, E., 1977, Infidelity of DNA synthesis as related to mutagenesis and carcinogenesis, J. Toxicol. Environ. Health, 2: 1297.PubMedCrossRefGoogle Scholar
  22. Maher, V. M., and McCormick, J. J., 1979, DNA repair and carcinogenesis, in: “Chemical Carcinogens and DNA,” P. L. Grover, ed., Vol. 2, p. 133, CRC Press, Boca Raton, Fla.Google Scholar
  23. Malling, H. V., 1971, Dimethylnitrosamine: Formation of mutagenic compounds by interaction with mouse liver microsomes, Mutation Res., 13: 425.PubMedCrossRefGoogle Scholar
  24. Markert, C. L., 1978, Cancer: The survival of the fittest, in: “Cell Differentiation and Neoplasia,” G. F. Saunders, ed., Raven Press, New York.Google Scholar
  25. Maugh, T. H., II, 1978, Chemicals: How many are there?, Science, 199: 162.PubMedCrossRefGoogle Scholar
  26. McCann, J., Choi, E., Yamasaki, E., and Ames, B. N., 1975, The detection of carcinogens as mutagens in the Salmonella microsome test: Assay of 300 chemicals, Proc. Natl. Acad. Sci., U.S.A., 72: 5135.PubMedCrossRefGoogle Scholar
  27. Miller, E. C., and Miller, J. A., 1971, The mutagenicity of chemical carcinogens: correlations, problems, and interpretations, in: “Chemical Mutagens — Principles and Methods for Their Detection,” Vol. 1, p. 83, A. Hollaender, ed., Plenum Press, New York.Google Scholar
  28. Miller, J. A., 1979, Concluding remarks on chemicals and chemical carcinogenesis, in: “Carcinogens: Identification and Mechanisms of Action,” A. C. Griffin and C. R. Shaw, ed., p. 455, Raven Press, New York.Google Scholar
  29. Miller, J. A., and Miller, E. C., 1978, Metabolic activation to reactive electrophiles: An overview, in: “Advances in Pharmacology and Therapeutics,” Y. Cohen, ed., Vol. 9, p. 3, Pergamon Press, Oxford/New York.Google Scholar
  30. Miller, J. A., and Miller, E. C., 1979, Perspectives on the metabolism of chemical carcinogens, in: “Environmental Carcinogenesis: Occurrence, Risk Evaluation, and Mechanisms,” P. Emmelot and E. Kriek, ed., p. 25, Elsevier/North Holland Biomedical Press, Amsterdam.Google Scholar
  31. Miller, J. A., Swanson, A. B., and Miller, E. C., 1979, The metabolic activation of safrole and related naturally occurring alkenylbenzenes in relation to carcinogenesis by these agents, in: “Naturally Occurring Carcinogens-Mutagens and Modulators of Carcinogenesis,” E. C. Miller, J. A. Miller, I. Hirono, T. Sugimura, and S. Takayama, ed., p. 111, Japan Scientific Societies Press, Tokyo.Google Scholar
  32. Mintz, B., 1978, Genetic mosaicism and in vivo analyses of neoplasia and differentiation, in: “Cell Differentaition and Neoplasia,” G. F. Saunders, ed., p. 27, Raven Press, New York.Google Scholar
  33. Moore, P. D., and Koreeda, M., 1976, Application of the change in partition coefficient with pH to the structure determination of alkyl substituted guanosines, Biochem. Biophys. Res. Commun., 73: 459.PubMedCrossRefGoogle Scholar
  34. O’Connor, P. J., Saffhill, R., and Margison, G. P., 1979, N-Nitrosocompounds: Biochemical mechanisms of action, in: “Environmental Carcinogenesis: Occurrence, Risk Evaluation, and Mechanisms,” P. Emmelot and E. Kriek, ed., p. 73, Elsevier/North Holland, Amsterdam.Google Scholar
  35. Oesch, F., 1973, Mammalian epoxide hydrases: Inducible enzymes catalyzing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds, Xenobiotica, 3: 305.PubMedCrossRefGoogle Scholar
  36. Oswald, E. O., Fishbein, L., Corbett, B. J., and Walker, M. P., 1971, Identification of tertiary aminomethylenedioxypropiophenones as urinary metabolites of safrole in the rat and guinea pig, Biochim. Biophys. Acta, 230: 237.PubMedCrossRefGoogle Scholar
  37. Phillips, D. H., Miller, J. A., Miller, E. C., and Adams, B., 1981, Structures of the DNA adducts formed in mouse liver after administration of the proximate hepatocarcinogen l′-hydroxyestragole, Cancer Res., in press.Google Scholar
  38. Pitot, H. C., and Sirica, A. E., 1980, The stages of initiation and promotion in hepatocarcinogenesis, Biochim. Biophys. Acta, 605: 191.PubMedGoogle Scholar
  39. Poland, A., and Glover, E., 1979, An estimate of the maximum in vivo covalent binding of 2,3,7,8-tetrachlorodibenzo-pdioxin to rat liver protein, ribosomal RNA, and DNA, Cancer Res., 39: 3341.PubMedGoogle Scholar
  40. Purchase, I. F. H., Longstaff, E., Ashby, J., Styles, J. A., Anderson, D., Lefevre, P. A., and Westwood, F. R., 1978, An evaluation of 6 short-term tests for detecting organic chemical carcinogens, Brit. J. Cancer, 37: 873.PubMedCrossRefGoogle Scholar
  41. Rinkus, S. J., and Legator, M. S., 1979, Chemical characterization of 465 known or suspected carcinogens and their correlation with mutagenic activity in the Salmonella typhimurium system, Cancer Res., 39: 3289.PubMedGoogle Scholar
  42. Rubin, H., 1980, Is somatic mutation the major mechanism of malignant transformation?, J. Natl. Cancer Inst., 64: 995.PubMedGoogle Scholar
  43. Schulte-Hermann, R., 1974, Induction of liver growth by xenobiotic compounds and other stimuli, CRC Rev. Toxicol., 3, 97.CrossRefGoogle Scholar
  44. Searle, C. E., ed., 1976, “Chemical Carcinogens,” ACS Monograph 173, American Chemical Society, Washington, D.C.Google Scholar
  45. Slaga, T. J., Fischer, S. M., Nelson, K., and Gleason, G. L., 1980, Studies on the mechanism of skin tumor promotion: Evidence for several stages in promotion, Proc. Natl. Acad. Sci., U.S.A., 77: 3659.PubMedCrossRefGoogle Scholar
  46. Slaga, T. J., Sivak, A., and Boutwell, R. K., ed., 1978, “Mechanisms of Tumor Promotion and Cocarcinogenesis,” Raven Press, New York.Google Scholar
  47. Solheim, E., and Scheline, R. R., 1973, Metabolism of alkenebenzene derivatives in the rat. I. p-Methoxyallybenzene (estragole) and p-methoxypropenylbenzene (anethole), Xenobiotica, 3: 493.PubMedCrossRefGoogle Scholar
  48. Stillwell, W. G., Carman, M. J., Bell, L., and Horning, M. G., 1974, The metabolism of safrole and 2′,3′-epoxysafrole in the rat and guinea pig, Drug. Metab. Dispos., 2: 489.PubMedGoogle Scholar
  49. Sugimura, T., Sato, S., Nagao, M., Yahagi, T., Matsushima, T., Seino, Y., Takeuchi, M., and Kawachi, T., 1976, Overlapping of carcinogens and mutagens, in: “Fundamentals in Cancer Prevention,” P. N. Magee, S. Takayama, T. Sugimura, and T. Matsushima, ed., p. 191, University Park Press, Baltimore.Google Scholar
  50. Swanson, A. B., Chambliss, D. D., Blomquist, J. C., Miller, E. C., and Miller, J. A., 1979, The mutagenicities of safrole, estragole, eugenol, trans-anethole, and some of their known or possible metabolites for Salmonella typhimurium mutants, Mutation Res., 60: 143.PubMedCrossRefGoogle Scholar
  51. Thompson, L. H., Baker, R. M., Carrano, A. V., and Brookman, K. W., 1980, Failure of the phorbol ester 12–0-tetradecanoylphorbol-l3-acetate to enhance sister chromatid exchange, mitotic segregation, or expression of mutations in Chinese hamster cells, Cancer Res., 40: 3245.PubMedGoogle Scholar
  52. Tomasz, M., 1970, Extreme lability of the C-8 proton: A consequence of 7-methylation of guanine residues in model compounds and in DNA and its analytical application, Biochim. Biophvs. Acta, 199: 18.Google Scholar
  53. Van Duuren, B. L., 1976, Tumor-promoting and co-carcinogenic agents in chemical carcinogenesis, in: “Chemical Carcinogens,” ACS Monograph 173, C. E. Searle, ed., p. 24, American Chemical Society, Washington.Google Scholar
  54. Windholz, M., ed, 1976, “The Merck Index,” 9th Ed., Merck & Co., Rahway, N.J.Google Scholar
  55. Wislocki, P. G., Borchert, P., Miller, J. A., and Miller, E. C., 1976, The metabolic activation of the carcinogen l′-hydroxysafrole in vivo and in vitro and the electrophilic reactivities of possible ultimate carcinogens, Cancer Res., 36: 1686.PubMedGoogle Scholar
  56. Wislocki, P. G., Miller, E. C., Miller, J. A., McCoy, E. C., and Rosenkranz, H. S., 1977, Carcinogenic and mutagenic activities of safrole, l′-hydroxysafrole, and some known or possible metabolites, Cancer Res., 37: 1883.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1982

Authors and Affiliations

  • Elizabeth C. Miller
    • 1
  • James A. Miller
    • 1
  1. 1.McArdle Laboratory for Cancer ResearchUniversity of WisconsinMadisonUSA

Personalised recommendations